Introduction: Botox® (serotype A) is currently available and used to treat various ophthalmological conditions. The aim of our study was to review the current indications, side-effects and updates on the clinical use of botulinum toxin-A (Btx-A) in the field of ophthalmology.
INTrODUcTION
Botulinum toxin (Btx) is derived from the bacteria Clostridium Botulinum. It degrades the SNARE proteins in the axon terminal and inhibits the release of neurotransmitters like acetylcholine that are necessary for nerve signal conduction 1 . It was first described as a therapeutic modality for strabismus in humans in 1981 by Alan Scott 2 . There are currently two commercially available serotypes for therapeutic use, Botulinum Serotype A (Btx-A; eg. Botox®, Dysport®, Xeomin®) and Serotype B (Btx-B; eg. MyoBloc®). Botulinum toxin A (Btx-A) is currently the serotype that is most described in the literature for the treatment of various medical conditions which include migraine, benign essential blepharospasm and hyperhidrosis, to name a few. The toxin can take effect within three days and may have maximal effect at two to four weeks. Its effects have been reported to last three to four months on average but may range from weeks to six months 3 .
In our clinical practice, Botox® (serotype A) is currently available and used to treat various ophthalmological conditions. The aim of our study was to review the current indications, side-effects and updates on the clinical use of botulinum toxin (Btx-A) in the field of ophthalmology.
METHODs
A literature search using the keywords "Botulinum Toxin", "Botulinum Toxin A", "Botox" and "Ophthalmology" was performed using Pubmed. Articles describing the use of botulinum toxin Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 A were selected and reviewed. Each specific indication of Btx-A was also searched against "Botulinum toxin A". The results of the studies are summarised in this review.
rEsULTs AND DIscUssION
The uses of Btx-A in ophthalmology can be broadly classified into four categories: eyelid, strabismus, cosmetic uses and others. A summary can be found in Table 1 3, 4 . In practice, Botox® is reconstituted by adding normal saline into a commercially prepared Botox® vial that contains the toxin in powder form to a concentration of five to 10 U per 0.1ml. The target injection site can be localised with electromyographic (EMG) guidance by inserting the EMG probe into the involved muscle. This is especially useful when localising the extraocular muscle for injection in the correction of strabismus. Before the administration of Btx to patients, the clinician should be aware of the following relative contraindications and it is recommended that we avoid this drug in the following situations 5 : (1) Patients with peripheral motor neuropathic disease eg. myasthenia gravis; for fear of potentiating their systemic disease with increased risk of side-effects;
(2) Use of aminoglycoside antibiotics or other agents that can interfere with neuromuscular transmission and potentiate Btx effects should be avoided; (3) Inflammatory or infective skin conditions where the injection is to be administered; the injection might worsen the existing skin condition or introduce the infection into the deeper dermal layers which might prove more difficult to treat; (4) Pregnancy and lactation as the effects of the drug on the foetus and breastfeeding infant are unknown.
Eyelid

Blepharospasm
Blepharospasm is a focal dystonia characterised by recurrent involuntary contraction of the orbicularis oculi muscles leading to frequent blinking or forceful eyelid closure. This is a lifelong condition that has a significant impact on a patient's quality of life 6 . Btx-A has received Food and Drug Administration (FDA) approval for use in the treatment of essential blepharospasm and hemifacial spasm. A review by the Cochrane group 7 found a few controlled clinical trials [8] [9] [10] [11] and these trials had short follow-up duration with small patient numbers. These studies, along with large cohort and case control studies, support botulinum toxin A as the treatment of choice for blepharospasm, with 90% of the patients benefiting from the injection of Botulinum toxin A when compared to placebo.
In a review by Dutton et al 12 , they found 29 published series that showed Btx-A to be effective in 75 to 100% of patients with a mean success rate of 93.3%. The average dose of Btx-A used was 12.5 to 25 U per eye for Botox and 50 to 100 U for Dysport, injected through the skin into the orbicularis muscle. The medial and lateral portions of the upper and lower lid pre-septal orbicularis muscle are the most common injection sites.
As there are now a number of different formulations of Btx-A available on the market, randomised controlled trials have been conducted to compare their relative safety and efficacy in the treatment of blepharospasm. Dysport® is a highly purified formulation of Btx-A that was found to be safe and efficacious in a phase II, multicentre, double-blind, randomised, parallel-group, placebo-controlled study that evaluated a single injection regimen of placebo, 40, 80, or 120 units per eye of Dysport® in patients with bilateral essential blepharospasm 13 . The best balance of sustained efficacy and favourable safety profile was provided by 80 units of Dysport® per eye in this study. In an earlier study by Nussgens et al 14 , where 212 consecutive patients were randomised to be treated with one drug first followed by the second, there was no statistically significant difference in the duration of the treatment effect between them but there were fewer side-effects noted with Botox® than Dysport® (P <0.05). This difference was highlighted in the group with ptosis where a significantly lower rate of ptosis was noted in the group with Botox (P <0.01). In the later study by Sampaio et al which included 91 patients 15 , a similar clinical efficacy and tolerability was noted between the two groups. Both studies employed a bioequivalent ratio of Botox® to Dysport® of 1:4.
On comparing Botox® and Prosigne, there was similar efficacy and safety profile in the treatment of blepharospasm and hemifacial spasm in two randomised controlled studies 16, 17 . A newer formulation called Xeomin® is free of the noncovalently associated non-toxic and inactive complexing proteins 18 . In view of its lower molecular weight, it is thought to be less immunogenic and less likely to stimulate an antibody reaction that may neutralise the neurotoxic effect of Botulinum toxin. It has been shown to be safe and efficacious 18 and comparable to Botox 19, 20 . Longer duration of follow-up with recurrent use is needed to determine if the protein-free formulation does indeed have an effect on the host immunogenicity. Meditoxin is a formulation of Btx-A which is produced in South Korea. In a double-blind randomised, comparative study, Meditoxin and Botox were found to be comparable in efficacy and safety in the treatment of essential blepharospasm 21 .
Btx-B (Botulinum toxin serotype B) (Myobloc®) can be used to treat patients who are refractory to type A botulinum toxin 22 . The authors found that it was an effective treatment when used on patients who had become refractory to Btx-A. However, Btx-B has a shorter duration of effect, with a tendency to diffuse into the surrounding tissue with attending undesirable effects and causes more pain on injection.
One or more side-effects of Btx-A injections can occur in up to 30% of the patients treated for blepharospasm 12 . Reported complications include those related to (1) the injection e.g. (a) ecchymosis (b) pain (c) infection, and (2) effects of the neurotoxin e.g (a) ptosis, (b) diplopia, (c) lagophthalmos (incomplete eyelid closure), (d) mid facial weakness and (e) dry eyes. Due to the limited duration of effect of Btx-A which usually lasts three to four months, repeat injections are required to maintain its treatment effect. Of the above mentioned complications, ptosis is the most common 23 and the risk increases with the number of injections. The rate of ptosis increases to 74% by the time a patient receives 10 injections 24 . This risk also increases with the dose of the Btx-A injection given 24, 25 .
A study by Boyle et al found that in a group of 16 patients, a higher concentration of botulinum toxin A resulted in a 58% reduction in perceived pain 26 . There was no reported difference in efficacy or complications experienced. Dry eye commonly develops post Btx-A injection and usually results from a decreased blink reflex and lagophthalmos. This can be seen in up to 64% of patients 27, 28 . However, a group from the University of Sao Paolo has reported a therapeutic effect of Btx-A in the relief of dry eye symptoms in blepharospasm 29, 30 . A group led by Horwath-Winter reported an improvement only in the blepharospasm but not in dry eye symptoms 31 .
Induce Ptosis/Reduce Lid Retraction
Btx can be used to chemically denervate the eyelids to induce ptosis. This has a therapeutic indication in the management of lid retraction in thyroid eye disease (TED), neurotrophic keratopathy or Bell's palsy when the managing clinician wants to improve eye closure in order to protect the cornea.
In TED, the lid retraction can result in incomplete eye closure with instability of the ocular surface Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 that may lead to cornea ulceration. Moreover, lid retraction is also considered a cosmetic blemish to some of these TED patients and Btx injection is a good alternative for patients who wish to defer surgical correction. Btx-A injection has been shown to induce a drop of 2 to 3mm in lid height for eight to 14 weeks [32] [33] [34] [35] [36] [37] . The Btx-A can be injected subconjunctivally or transcutaneously. In 2002, Uddin et al injected Btx-A transconjunctivally in the upper eyelid of 11 thyroid eye disease patients with lid retraction. Ten of the 11 patients felt their lid achieved an acceptable position after the injection with the effects lasting one to 40 months 38 .
When injected via a transcutaneous approach, Btx-A can achieve similar lid lowering effects with good safety and efficacy 34, 35, 37, 39 . In addition, the study by Costa et al found the lid lowering effects of Btx-A lasted longer in patients with fibrotic-stage TED as compared to patients with congestive-stage TED 40 .
This procedure has a five to 10% risk of overcorrection that might result in ptosis and a 10% risk of transient diplopia 41 .
Cornea protection is desirable in Bell's palsy, neurotrophic ulcers or persistent epithelial defects in graft patients. An injection of Btx-A has been shown to induce sufficient ptosis to provide the cornea with adequate protection 42, 43 . This can help patients avoid the need for a tarsorapphy 43 . In a prospective interventional case series by Naik et al, 10 patients who were diagnosed with Bell's palsy, persistent epithelial defect or neurotrophic ulcer had Btx-A injected into the levator palpebrae superioris to induce ptosis to protect the cornea 44 . More than 50% reduction in palpebral fissure height was seen in nine out of 10 eyes (90%, 95% CI 71.4-100%) at one week and two of nine eyes (22.2%, 95% CI 0-49.4%) at four weeks. The lid height returned to pre-treatment level after a mean duration of 9.2 weeks (range 5-16 weeks).
Apraxia of Lid Opening
Apraxia is defined as an inability to execute learned purposeful movements despite having the desire and physical ability to perform the movements. Apraxia of eyelid opening refers to the inability to raise the upper eyelid in the absence of levator muscle injury, paralysis or orbicularis oculi muscle contraction. It has been described in isolation or in association with other extrapyramidal disorders like Parkinson syndrome and progressive supranuclear palsy 45 . This condition is amenable to botulinum toxin injections in blepharospastic apraxia where contractions of the pretarsal orbicularis oculi muscle suppress the levator contraction 46, 47 . Btx-A injections into the pretarsal orbicularis oculi allows the levator action to resume and has some beneficial effect on eyelid opening in this subset of patients 46, [48] [49] [50] [51] .
Entropion
Lower lid entropion may arise due to spastic contraction of the pretarsal orbicularis oculi muscle resulting in turning of the lid margin. This can result in ocular surface irritation from the inturned eyelashes and propagate a vicious cycle of ocular irritation and further lid spasticity. Injection of five to 10 units of Btx-A into the pretarsal or preseptal orbicularis muscle can eliminate the spastic component of the entropion 25, [52] [53] [54] . This can provide the patient with temporary relief while awaiting definitive entropion surgery or as a long-term treatment modality in the elderly patient who is deemed unfit for surgery. strabismus Strabismus, or more commonly known as "squint", is an ocular condition where there is a loss of eye alignment. One eye may deviate inwards (esotropia), outwards (exotropia), upwards (hypertropia), downwards (hypotropia) or rotate (cyclotropia). This may be present intermittently or constantly and may develop in childhood or adulthood. There are many causes for strabismus and can include neuromuscular disease, for example myasthenia gravis, nerve palsies (eg. 3 rd or 6 th nerve palsy), poor vision in the involved eye and muscle contracture (eg. fibrosis of extraocular muscles in thyroid eye disease). Consequences of ocular misalignment include amblyopia (permanent blurred vision in the involved eye), loss of binocular function and stereopsis (3-dimensional and depth perception) and diplopia. Treatment options include use of prisms to realign the visual axes, orthoptic exercises to improve coordination between the two eyes, extraocular muscle (squint) surgery and botulinum toxin 55 .
There are many studies that have been conducted using botulinum toxin as treatment for strabismus. However, only four randomised controlled trials have been performed [56] [57] [58] [59] . In the 1998 study by Tejedor 58 requiring retreatment were randomised to receive either reoperation or Btx-A injection. In 1999, a similar study was performed on 55 children with infantile esotropia requiring retreatment 59 . Both studies showed a similar safety and efficacy profile between the repeat squint surgery and Btx-A injections for a follow-up duration of approximately two to three years. In the study by Carruthers, 30 adults with esotropia or exotropia without binocular function were randomised to receive either an injection of Btx-A or squint surgery. The authors found that squint surgery was more effective than Btx-A treatment.
Other studies have shown its safety and efficacy in infantile esotropia [60] [61] [62] . However, there have been variable results as the age of patients and pattern of injection differ between the studies 63, 64 . One main effect to consider is that Botulinum toxin usually has a finite duration of action. There is risk of recurrence of the squint once its effects wear off as demonstrated in the study by Spielmann 65 . Another study by Tejedor showed that repeated injections might increase the success rate of the modality of treatment in acquired esotropia 66 . Increasing the dose of the Btx-A injection may also give better results but this may be associated with a higher incidence of complications like ptosis 67 .
Locally, 72% of children ≤16 years with horizontal strabismus have exotopia of which 92% of them have intermittent exotropia 68 . The efficacy of Btx-A in this condition was described by a group in China in a prospective non-randomised comparative study where success rate after surgery was compared to Btx-A injection and was found to be equally efficacious 69 . Another study by Spencer et al supported the efficacy of this treatment modality in 32 neurologically normal children with intermittent exotropia 70 . However, locally, Botox is reserved for acute, acquired, isolated cranial nerve palsies that are limited in a single direction of gaze, for example 6 th nerve palsy or thyroid eye disease and is not used in children.
Botulinum injections can also be administered in 6 th nerve palsies caused by trauma, ischaemia, tumours or inflammation 71 . Results of published studies to date have been controversial. In Singapore, 19 patients received 25 injections of whom seven achieved within 10 prism dioptres of orthotropia (ocular alignment) 72 . Other reports have supported this modality of treatment as recovery rates after injection were better than rates of spontaneous recovery in 6 th nerve palsy. When treatment is initiated less than six months from onset, recovery rates have been reported to be 38 to 70%, higher than spontaneous rates of recovery (12-54%) 71, 73 . However, in the setting of an acute traumatic 6 th nerve palsy, it is advisable to monitor patients first and await spontaneous recovery as recovery rates are high in this subset of patients 74, 75 . In a randomised controlled trial by Lee et al 57 , 54 patients with acute unilateral 6 th nerve palsy were randomised into one group that received Btx-A injection versus the other group where no treatment was administered. Both groups did equally well with recovery of their ocular movements and normal binocular single vision. In a prospective multicentre nonrandomised data collection study by Holmes of chronic 6 th nerve palsy, 56 patients underwent botox alone, surgery alone, botox and surgery or conservative management. The authors found that botox treatment alone was rarely successful with a similar recovery rate as patients who were conservatively managed 76 . Sanjari et al found that the results of injection were equal whether or not electromyographic (EMB) guidance was employed to localise the injection site and medial rectus muscle 77 . Kao and Chao described a sub-tenon's injection of Btx-A (without EMG guidance) to be just as efficacious and these patients had a higher rate of recovery than those who were allowed spontaneous recovery 78 . When treating large angle deviation due to 6 th nerve palsies, Btx-A injections are described as an adjunctive therapy to vertical muscle transposition to achieve the desired angle of correction 79, 80 .
In TED, Btx-A injections have also been described as efficacious in restrictive strabismus which is when there is large angle deviation of the eye in the direction of a tight, fibrotic muscle and the injection is administered into this tight muscle 81, 82 .
Generally, smaller angle strabismus is easier to correct with Btx-A treatment alone as compared to larger angle strabismus 83 . Apart from being used as primary treatment for strabismus, Btx-A can also be used as an adjunct to correct for residual strabismus after primary surgery in large angle strabismus. This can save the patient from undergoing a second surgery with its attending risks 84, 85 .
Complications of Btx-A injection for strabismus
Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 were described by Rowe et al and include vertical deviation, subconjunctival haemorrhage and ptosis. The overall incidence of complications in this study was 12.4% with all of them resolving by six weeks of follow-up 86 . Incidence of ptosis can range from one to eight percent 61, 86, 87 .
cosmetic
Of late, there has been an interest in Btx-A use in facial aesthetics 5, 88 . It can be injected into the forehead (glabellar lines), lateral angles of the eyes (crow's feet) and into the area between the brows (bunny lines) to alleviate wrinkling in these areas and minimise the "aged look" in a patient. The facial muscles are dynamic and work in coordination with each other. Chemodenervation of one set of muscles will exert some effect on the surrounding facial muscles and hence the appearance of the patient. Careful pre-procedural planning and patient involvement and understanding are crucial in order to set realistic treatment goals and to achieve the desired outcome for the patient 5 .
The efficacy of Btx-A (Botox® and Dysport®) injections in the treatment of glabellar lines compared to placebo was reported in four randomised controlled trials [89] [90] [91] [92] [93] [94] [95] . These studies were conducted in Caucasian (3) 89-91 , African American(1) 92 , Japanese (2) 93, 94 and Chinese(1) 95 populations. In all the studies, physician or subject rating of treatment effect was significantly greater in the treatment arm as compared to placebo, with minimal incidence of side-effects. When repeat doses of Btx-A injection were given, there was no evidence of cumulative safety issues, and the incidence of adverse events might even decrease over time 96, 97 . The optimal dose for treatment was evaluated in a randomised controlled trial by Monheit et al. All doses were well-tolerated but it was felt that the 50 U dose was as effective as the 75 U dose with a similar duration of effect based on patient and physician assessment 98 .
When used to treat crow's feet, it can either be injected or applied topically. Injection of Btx-A resulted in improvement in crow's feet severity when compared with placebo as rated by both physician and patient 99, 100 . A dose-dependent treatment effect was observed, with a greater magnitude and duration of effect with higher doses 100 . When applied topically, the BoNTA topical cream (CosmeTox) treatment resulted in significant improvements in scores that patients used to grade their facial lines. This score improvement was maintained throughout the study period and lasted more than three months. The topical cream treatment also reduced the patient's self-perception of age of appearance for a majority of subjects. The placebo had no effect on any measure 101 .
The long-term safety profile for use in all facial areas was recently described 5 . No serious adverse events have been reported and mild side-effects have included brow ptosis, eyelid ptosis, local pain, bruising and infection 23 . Headache has also been described but one study showed an equal incidence of headache in placebo treated patients(18%) compared to patients in the treatment arm (13%), suggesting that the headache is more likely due to the injection technique than the drug itself 102 .
Others
Lacrimal Hypersecretion (Excessive Tearing)
A subset of patients who have aberrant regeneration of their 7 th cranial nerve may develop a condition called gustatory epiphora or crocodile tears, which is when there is excessive tearing (lacrimation) with salivatory stimulation 103 . Ocular surface irritation by malposition of the eyelid and eyelashes may also result in excessive tearing. Injection of 2.5 to 5 units of Btx-A into the palpebral lobe of the lacrimal gland can result in a reduction of tear production and symptomatic improvement in up to 75% of patients [103] [104] [105] [106] [107] . The effects of the injection, with relief of excessive tearing, can last up to three to four months.
Chronic Dry Eye
Dry eye is due to an imbalance in the composition of the aqueous, mucin and lipid layers of the tear film. The aqueous component is produced by the lacrimal gland and drained by the lacrimal drainage system. This drainage system consists of the lacrimal pump that is located in the medial canthal region of the eye and its mechanism of action is regulated by the orbicularis oculi during blinking. In blepharospasm or hemifacial spasm, a chronic dry eye state may result due to the excessive blinking and some studies have shown relief from dry eye symptoms when this blink rate is reduced by Btx-A injections 29, 30 . However, a study by Horwath found that the blepharospasm is relieved but dry eye symptoms persist despite the injection 31 . In isolated chronic dry eye, Sahlin has published two reports describing the relief of dry eye symptoms in up to 70% of their patients when Review Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 the Btx-A injection is administered into the medial portion of the upper and lower eyelids to minimise the lacrimal pump action, thus allowing the tears to pool in the fornix and provide symptomatic relief 108, 109 .
Periorbital Pain Relief after Acute Angle Closure Glaucoma
A novel application of Btx-A is its use to relieve periorbital pain after an acute angle closure glaucoma attack 110 . However, this application has to be viewed and applied with caution as botulinum toxin inhibits acetylcholine release which can result in pupil mydriasis. In 1990, a case report was published of a patient who developed an acute angle closure attack after botulinum toxin injection was administered to treat blepharospasm 110 .
cONcLUsION
The clinical application of botulinum toxin A in ophthalmology is extensive. When considering its application in clinical practice, one should be mindful of the indications, risks and benefits of the procedure. When properly delivered, its potential as an efficacious, minimally-invasive treatment modality can be maximised in patient management.
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